Thread: Stem Cell Articles

  1. #1331
    Embryos Discarded During IVF Create Stem Cell Lines

    Study says it's a possible source for such cell lines without the ethical issues
    Posted 1/28/08

    MONDAY, Jan. 28 (HealthDay News) -- Embryos discarded from in vitro fertilization (IVF) clinics can be used to create stem cell lines, new research suggests.

    Researchers from Children's Hospital Boston said this is the first study to show it's possible to derive stem cells from poor-quality IVF embryos, which could prove to be an important source of stem cells for research. Their report is published in the Jan. 27 online edition of Nature Biology.


  2. #1332
    Stem cell transplants may be beneficial for stroke victims

    Washington, January 28 (ANI): Two separate studies have shown that human mesenchymal stem cell (hMSC) and bone marrow stromal cell (BMSCs) transplantation, respectively, may be beneficial for stroke victims.
    Both studies tracked the migration of chemically tagged transplanted stem cells to determine the degree to which the transplanted cells reached damaged areas of the brain, and became therapeutically active.

    One of the studies was conducted by Korean researchers, wherein hMSCs were transplanted into animal stroke models with cerebral artery occlusion and tracked by magnetic resonance imaging (MRI) at two days, one week, two weeks, six weeks and ten weeks after transplant.


  3. #1333
    NYU gets $1.5m for stem cell research

    Jane C. Timm and Reem Nasr
    Issue date: 1/28/08 Section: University


    Two NYU research institutions received a combined grant of $1.5 million from New York State to fund stem cell research, the state press office announced Jan. 7.

    The NYU Medical Center and the Office of the Dean for Science were awarded $999,715 and $553,000, respectively, from a $14.6 million fund that the state hopes will jump-start its biomedical research capabilities.


  4. #1334
    Flawed embryos seen as source for stem cells

    By Colin Nickerson

    Globe Staff / January 28, 2008

    From what is now considered medical waste might be fashioned bio-treasure: stem cells able to form into any of the body's 220 cell types, including blood, nerves, bone, and skin tissue, new research suggests.

    The poor quality embryos are "an ethically acceptable source" for

    the creation of stem cell lines.

    Scientist George Q. Daley

    Scientists at Children's Hospital Boston have forged stem cells from the "flawed" and "poor quality" early-stage embryos that in vitro fertilization clinics discard by the hundreds of thousands every year, according to research published yesterday in the journal Nature Biotechnology.

    These are embryos created by IVF technicians but culled because abnormalities make them unsuitable for implantation into the wombs of women unable to conceive naturally. The embryos, usually containing no more than a few score cells, are deemed medical waste and simply tossed away.

    Such embryos can "provide a reliable source for embryonic stem derivation," said Dr. Paul H. Lerou, lead author of the study and a neonatologist at Children's and Brigham & Women's Hospital.

    Stem cells are thought to represent medicine's single best hope for healing damaged heart cells, mending shattered spinal cords, and curing or treating an array of other horrendous afflictions.

    The cells derived from low-quality embryos may be limited to use in general stem cell research because they might carry tiny abnormalities making them too risky for direct patient therapy, said George Q. Daley, a stem cell scientist at Children's and the study's senior author.


  5. #1335
    Pahang to Host World's Largest Stem Cell Manufacturing Plant

    By Jeeva Arulampalam

    THE East Coast Economic Region (ECER) will host the world's largest stem cell manufacturing facility when US-based Bio-Cellular Research Organisation (BCRO) sets up operations there.

    Pahang Technology Resources Sdn Bhd and BCRO Stem Cell Xenotransplantation Sdn Bhd will sign a memorandum of understanding on January 28, witnessed by Prime Minister Datuk Seri Abdullah Ahmad Badawi, the ECER Secretariat said in a statement issued yesterday.


  6. #1336
    Unhappy With New Stem Cell Source? Then Stop Having Sex

    By Brandon Keim January 28, 2008 | 12:52:02 PMCategories: Bioethics, Stem Cell Research

    Scientists have produced embryonic stem cells from embryos that would otherwise be thrown away.

    The findings, published yesterday in Nature Biotechnology by researchers from Children's Hospital Boston, raise hopes -- again -- of an ethically acceptable source for the potentially miraculous, highly controversial cells.

    If the latest cells don't satisfy critics, says a prominent bioethicist, the critics might want to stop having sex.

    Embryonic stem cells, or ESCs, have the power to become any other type of cell. They might someday be used to replace diseased or failing tissue. But the best source for ESCs is week-old human embryos. The embryos are destroyed during harvesting, drawing charges of murder from religiously conservative critics. President Bush has limited federal funding for ESC research, and the controversy has slowed ESC progress in the United States.


  7. #1337
    Indian origin researcher highlights stem cell activation's role in bone repair

    Washington | January 28, 2008 5:21:59 PM IST

    A new study authored by an Indian origin researcher suggests that a medication, which is used to activate stem cells to treat bone marrow cancer, may also offer a potential therapy for osteoporosis.

    Dr. Siddhartha Mukherjee of Massachusetts General Hospital (MGH) and the Harvard Stem Cell Institute (HSCI) writes that the medicine called bortezamib (Bzb) has been found to improve bone density in a mouse model of osteoporosis during experiments.

    The author says that the improvement might be attributable to the medicine's effect on the mesenchymal stem cells (MSCs), which differentiate into several types of tissues.

    MSCs are found in the bone marrow, and they have the potential to develop into the bone-building osteoblasts and several other types of cells like cartilage, fat, skin and muscle.

    "Stem cell therapies are often thought of as putting new cells into the body, but this study suggests that medications can turn on existing stem cells that reside in the body's tissues, acting as regenerative medicines to enhance the body's own repair mechanisms," says Dr. David Scadden, director of the MGH Center for Regenerative Medicine and HSCI co-director.


  8. #1338
    Protein that controls hair growth also keeps stem cells slumbering

    Medical Research News
    Published: Monday, 28-Jan-2008

    Like fine china and crystal, which tend to be used sparingly, stem cells divide infrequently.
    It was thought they did so to protect themselves from unnecessary wear and tear. But now new research from Rockefeller University has unveiled the protein that puts the brakes on stem cell division and shows that stem cells may not need such guarded protection to maintain their potency.

    This research, to be published in the January 25 issue of Cell, raises questions about what stem cells need in order to maintain their ability to regenerate tissue. It may also be key in developing new treatments for thinning hair.

    The impetus for the work began five years ago when Elaine Fuchs, head of the Laboratory of Mammalian Cell Biology and Development, and several researchers in her lab discovered that the protein NFATc1 was one of only a few that are highly expressed within the stem cell compartment of the hair follicle. Clinical research, meanwhile, showed that a particular immunosuppressant that inhibits NFATc1, a drug called cyclosporine A, has a rather unsightly side effect: excessive hair growth.


  9. #1339
    Senior Member Bhaskar's Avatar
    Join Date
    Feb 2006
    Kolkata, India

    Organ Donor's Marrow to prevent immune rejection trials

    Northwestern Memorial trial may wean kidney transplant patients off antirejection drugs

    New study transplants stem cells from a kidney donor's bone marrow into the recipient, with the hope of gradually eliminating the need for antirejection drugs
    CHICAGO — After a transplant surgery, anti-rejection drugs for the organ recipient are a must, but with prolonged use can have serious side effects, including infections, heart disease and cancer. A team led by Joshua Miller, MD, a researcher at Northwestern University's Feinberg School of Medicine, is working with Northwestern Memorial Hospital's department of organ transplantation to enroll qualifying subjects in a new research study that seeks to transplant stem cells from a kidney donor's bone marrow into the recipient, with the hope of gradually eliminating the need for anti-rejection drugs. If research proves successful, it would mean a dramatic change in the post-transplant quality of life for the transplant recipient.

    Northwestern is the only center in Chicago and one of four centers nationally looking at this topic. The Feinberg School of Medicine has received a four-year, $2.5 million grant from the National Institutes of Health to enroll 20 patients in the study, which is called "Donor Stem Cells, Campath, T/B Cell Regulation In HLA-Identical Renal Transplants. "

    More :

  10. #1340
    Senior Member Bhaskar's Avatar
    Join Date
    Feb 2006
    Kolkata, India

    MAPCs for PAD

    Adult stem cell application effective in treatment of peripheric vascular disease
    Multipotent adult progenitor stem cells extracted from bone marrow, and known as MAPCs, have proved to be effective in the regeneration of blood vessel tissue and also in muscle tissue when treating peripheric vascular disease. This was the result of research undertaken with mouse models by two research groups, one by the University Hospital of Navarra jointly with the Centre for Applied Medical Research (CIMA), also of the University of Navarra, and the other by the Centre for Molecular and Vascular Biology atthe Catholic University of Leuven (Belgium).

    The results of the study have been recently published as an article in The Journal of Clinical Investigation the main author of which is doctor in Biology at the University Hospital of the University of Navarra and CIMA, Xabier López Aranguren. The study was part of a line of research for his PhD thesis. The directors of the current research are doctors Felipe Prósper, for the University Hospital of Navarra and CIMA and Aernout Luttun and Catherine M. Verfaille for the Catholic University of Leuven.

    More :

Similar Threads

  1. Replies: 105
    Last Post: 02-14-2007, 10:32 AM
  2. Replies: 3
    Last Post: 06-27-2006, 01:25 AM
  3. Republican Senate Leader Frist to back ESC research!
    By Donny247 in forum Funding, Legislation, & Advocacy
    Replies: 45
    Last Post: 08-09-2005, 08:00 AM
  4. Replies: 4
    Last Post: 08-07-2002, 11:30 AM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts